Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/18/2021 | $9.00 | Buy | HC Wainwright & Co. |
| 8/2/2021 | $6.00 | Neutral → Overweight | JP Morgan |
| 7/28/2021 | $4.00 → $14.00 | Equal-Weight → Overweight | Wells Fargo |
| 7/7/2021 | $7.00 | Buy | B. Riley Securities |
HC Wainwright & Co. initiated coverage of Infinity Pharmaceuticals with a rating of Buy and set a new price target of $9.00
JP Morgan upgraded Infinity Pharmaceuticals from Neutral to Overweight and set a new price target of $6.00
Wells Fargo upgraded Infinity Pharmaceuticals from Equal-Weight to Overweight and set a new price target of $14.00 from $4.00 previously
Gainers Infinity Pharmaceuticals (NASDAQ:INFI) shares increased by 23.7% to $0.04 during Wednesday's after-market session. Trading volume for this security closed at 3.2 million, accounting for 94.2% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $3.9 million. TransCode Therapeutics (NASDAQ:RNAZ) shares moved upwards by 15.55% to $1.04. The company's market cap stands at $2.1 million. Longeveron Inc. - Subscription Right (NASDAQ:LGVNR) shares increased by 14.94% to $0.01. Scinai Immunotherapeutics (NASDAQ:SCNI) shares increased by 11.45% to $1.46. Today's trading volume for this security ended up closing at 582.8K shares, which i
Avalo Therapeutics, Inc. (NASDAQ:AVTX) shares surged 68% to $0.2075. Avalo Therapeutics, on Sept 12, got notice from the Nasdaq as of Sept 11 the company’s securities had closing bid price of $0.10/less for 10 consecutive trading days. ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) gained 63.5% to $0.2101. Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) rose 31.8% to $20.15 after the company announced that alignment has been reached with the FDA on the global Phase 2 pivotal trial of RP-A501 for Danon Disease. Connexa Sports Technologies Inc. (NASDAQ:CNXA) gained 22.2% to $0.1090. Axcella Health Inc. (NASDAQ:AXLA) shares jumped 19.3% to $1.36 after jumping more than 59% on Tuesday. Alset Capita
Gainers Avalo Therapeutics (NASDAQ:AVTX) stock moved upwards by 54.3% to $0.19 during Wednesday's regular session. As of 13:30 EST, this security is trading at a volume of 254.7 million shares, making up 2392.7% of its average full-day volume over the last 100 days. The company's market cap stands at $3.8 million. Impel Pharmaceuticals (NASDAQ:IMPL) stock rose 51.99% to $0.84. Trading volume for this security as of 13:30 EST is 32.3 million, which is 3640.6% of its average full-day volume over the last 100 days. The company's market cap stands at $19.9 million. ZyVersa Therapeutics (NASDAQ:ZVSA) shares moved upwards by 40.46% to $0.18. Trading volume for this security as of 13:30 EST is 1
SC 13G/A - INFINITY PHARMACEUTICALS, INC. (0001113148) (Subject)
SC 13G/A - INFINITY PHARMACEUTICALS, INC. (0001113148) (Subject)
SC 13G/A - INFINITY PHARMACEUTICALS, INC. (0001113148) (Subject)
Combination will create a company with a diverse product development pipeline led by a planned new global Phase 2 clinical trial evaluating eganelisib in head and neck squamous cell carcinoma (HNSCC) Projected ~$100M cash balance of combined company expected to fund operations through mid-2025 and to clinical data over the next 12 to 24 months Companies to host conference call and webcast today at 8:00 a.m. ET MEI Pharma, Inc. (NASDAQ:MEIP) ("MEI"), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, and Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) ("Infinity"), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno
– MARIO-3 Update in Patients with 1L TNBC showing 52% increase in one-year progression free survival rate in ITT patient population compared to Impassion130 benchmark – – Business development discussions advancing with goal of announcing a partnership in Q1 2023 – – Cash runway into 2024 with $47.2 million in cash and cash equivalents at end of Q3 2022– – Investor conference call to be held today at 8:30 AM ET – Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) ("Infinity" or the "Company"), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced its third quarter 2022 financial results, provi
Infinity Pharmaceuticals, Inc. (NASDAQ:INFI), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, will host a conference call on Monday, November 14, 2022, at 8:30 AM ET to report its financial results for the third quarter of 2022. To access the conference call, please register at https://register.vevent.com/register/BId44f86e6a2af42faadbb2844131346a8. Upon registering, each participant will be provided with call details and access codes. All participants are encouraged to join 10 minutes prior to the start time. A live webcast of the conference call can be accessed from the Events & Presentations page
Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) ("Infinity" or the "Company"), a clinical-stage biotechnology company developing eganelisib, a potential first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced a series of actions designed to reduce the Company's burn rate and enhance our ability to maximize value of eganelisib, following the termination of its previously announced merger agreement with MEI Pharma, Inc. The Company continues to believe, based on the data generated to date, that eganelisib offers a near-term value creation opportunity that would be attractive to potential third-party acquirers. Infinity has advanced eganelisib toward the init
Eganelisib Remains Primary Value Driver for Infinity Infinity to Explore Strategic Alternatives to Maximize Value for Stockholders Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) ("Infinity"), a clinical-stage biotechnology company developing eganelisib, a potential first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, announced that it has terminated its previously announced merger agreement providing for the merger with MEI Pharma, Inc. ("MEI"). At a special meeting of MEI stockholders on July 23, 2023, MEI did not obtain MEI stockholder approval for the merger with Infinity, nor could MEI obtain approval for an adjournment of the special meeting. In the process o
MEI Pharma, Inc. (NASDAQ:MEIP) (the "Company") today reminded shareholders to vote FOR the pending transaction with Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) ("Infinity") in connection with the Company's special meeting on July 23, 2023. MEI issued the following statement: Our shareholders have the opportunity to shape the future of their MEI investment. By voting FOR the Infinity transaction today, you have the opportunity to participate in the upside potential of a combined company with: a diversified therapeutic pipeline; a team that brings clinical development and regulatory expertise; and the capabilities and resources to develop new oncology therapeutics for the benefi
8-K - INFINITY PHARMACEUTICALS, INC. (0001113148) (Filer)
8-K - INFINITY PHARMACEUTICALS, INC. (0001113148) (Filer)
8-K - INFINITY PHARMACEUTICALS, INC. (0001113148) (Filer)
4 - INFINITY PHARMACEUTICALS, INC. (0001113148) (Issuer)
4 - INFINITY PHARMACEUTICALS, INC. (0001113148) (Issuer)
4 - INFINITY PHARMACEUTICALS, INC. (0001113148) (Issuer)